Last reviewed · How we verify
NCT03671772
Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD
trial in REM Sleep Behavior Disorder in 170 participants. Completed in 27 April 2020.
27 April 2020
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 170 |
| Start date | 27 September 2018 |
| Primary completion | 27 April 2020 |
| Estimated completion | 27 April 2020 |
| Sites | 1 location across Hong Kong |
Conditions studied
- REM Sleep Behavior Disorder — all drugs for REM Sleep Behavior Disorder →
- Neurodegeneration — all drugs for Neurodegeneration →
Sponsor
Chinese University of Hong Kong
Who can join
40 and older, any sex, with REM Sleep Behavior Disorder or Neurodegeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective study with a mean of 5-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development of clinical disorders in first-degree relatives (FDRs) of idiopathic REM Sleep Behavior Disorder (RBD) patients and healthy controls.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Narrative Review on Biochemical Markers and Emerging Treatments in Prodromal Synucleinopathies.
Rissardo JP, Caprara ALF. · · 2025 · cited 5× · PMID 40136601 · DOI 10.3390/clinpract15030065
Verify or expand the search:
- PubMed search for NCT03671772
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for REM Sleep Behavior Disorder
Currently open trials in the same condition.
- NCT06797284 — The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders · NA · recruiting
- NCT07443293 — IMPACT 360 for Parkinson's Disease · Phase 2 · recruiting
- NCT06629207 — Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder · NA · recruiting
- NCT06441864 — Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder · NA · recruiting
- NCT06270290 — The COSP-RBD Study: Concussions and Contact Sports in RBD vs Controls · recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03671772 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 6 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03671772.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing